Last update 23 Jan 2025

Hangzhou Xiniao Biotechnology Co., Ltd.

Private Company|
2018|
Zhejiang Sheng, China

Overview

Tags

Immune System Diseases
Hemic and Lymphatic Diseases
Other Diseases
Universal CAR-T

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Hemic and Lymphatic Diseases1
Immune System Diseases1
Top 5 Drug TypeCount
Universal CAR-T1
Top 5 TargetCount
BCMA x CD191

Related

1
Drugs associated with Hangzhou Xiniao Biotechnology Co., Ltd.
Universal allogeneic anti-CD19/BCMA CAR T-cells(Hematology Hospital of Chinese Academy of Medical Sciences)
Target
BCMA x CD19
Mechanism
BCMA modulators [+1]
Active Org.
Hangzhou Xiniao Biotechnology Co., Ltd. [+1]
Originator Org.
Hematology Hospital of Chinese Academy of Medical Sciences
Active Indication
Autoimmune Haemolytic Anaemias
Inactive Indication-
Drug Highest PhasePhase 1
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Hangzhou Xiniao Biotechnology Co., Ltd.
NCT06733610
/ RecruitingPhase 1IIT
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA in Patients with Autoimmune Hemolytic Anemia Have Failed ≥ 3 Lines of Therapy
100 Clinical Results associated with Hangzhou Xiniao Biotechnology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Hangzhou Xiniao Biotechnology Co., Ltd.
Login to view more data
100 Deals associated with Hangzhou Xiniao Biotechnology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Hangzhou Xiniao Biotechnology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 02 Feb 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
1
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free